Loading
Life sciences · Journal article
Gynecologic Oncology · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
OBJECTIVES: To describe the current landscape of hormone replacement therapy (HRT) to treat surgical menopause following bilateral salpingo-oophorectomy (BSO) in individuals with hereditary ovarian cancer risk in British Columbia, Canada. We aimed to describe current use of HRT, identify factors associated with HRT use and identify potential barriers for uptake and access. METHODS: Individuals with germline pathogenic/likely pathogenic variants in an ovarian cancer susceptibility gene were identified through the BC Cancer Hereditary Cancer Program (HCP) Progeny database. A cross-sectional survey was administered to collect participant demographics, personal and family cancer history, and participant experiences with HRT. Descriptive statistics were used to characterize the sample and logistic regression used to explore associations between sociodemographic variables and reported HRT use. Open text fields were analyzed using inductive quantitative content analysis. RESULTS: In total, 374 responses were received from 1284 potential participants (29.1% response rate). Of participants who have had a BSO, 41% (101/245) report HRT use. In open-text responses, 22% of participants reported lack of support by healthcare professionals and 26% described gaps in counselling about HRT and surgical menopause. In the regression analysis, HRT use was less likely in individuals who: were of increasing age, reported a history of any cancer type and who reported receiving no counselling about HRT (all p < 0.0011 after Bonferroni correction). CONCLUSION: Barriers to HRT access and uptake exist for individuals at increased risk of ovarian cancer. Together this data indicates that patients require additional support in this area particularly as it relates to education and resources.